The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength
Open accessAbstract
Introduction: Sclerosteosis is a rare high bone mass genetic disorder in humans caused by inactivating mutations in SOST, the gene encoding sclerostin. Based on these data, sclerostin has emerged as a key negative regulator of bone mass. We generated SOST knockout (KO) mice to gain a more detailed understanding of the effects of sclerostin deficiency on bone. Materials and Methods: Gene targeting was used to inactivate SOST and generate a line of SOST KO mice. Radiography, densitometry, μCT, histomorphometry, and mechanical testing were used to characterize the impact of sclerostin deficiency on bone in male and female mice. Comparisons were made between same sex KO and wildtype (WT) mice. Results: The results for male and female SOST KO mice were similar, with differences only in the magnitude of some effects. SOST KO mice had increased radiodensity throughout the skeleton, with general skeletal morphology being normal in appearance. DXA analysis of lumbar vertebrae and whole leg showed that there was a significant increase in BMD (>50%) at both sites. μCT analysis of femur showed that bone volume was significantly increased in both the trabecular and cortical compartments. Histomorphometry of trabecular bone revealed a significant increase in osteoblast surface and no significant change in osteoclast surface in SOST KO mice. The bone formation rate in SOST KO mice was significantly increased for trabecular bone (>9-fold) at the distal femur, as well as for the endocortical and periosteal surfaces of the femur midshaft. Mechanical testing of lumbar vertebrae and femur showed that bone strength was significantly increased at both sites in SOST KO mice. Conclusions: SOST KO mice have a high bone mass phenotype characterized by marked increases in BMD, bone volume, bone formation, and bone strength. These results show that sclerostin is a key negative regulator of a powerful, evolutionarily conserved bone formation pathway that acts on both trabecular and cortical bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Threshold Selection Method from Gray-Level Histograms
Otsu, N. (1979) · IEEE Transactions on Systems, Man, and Cybernetics · doi:10.1109/tsmc.1979.4310076 · Cited by 43,398
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Self-citationLittle, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“Mutations in a previously undescribed gene, SOST, were identified by positional cloning as being responsible for causing sclerosteosis.((3,4)) Sclerostin, the pro-”
BackgroundOsteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 1×
“Mutations in a previously undescribed gene, SOST, were identified by positional cloning as being responsible for causing sclerosteosis.((3,4)) Sclerostin, the pro-”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Cited by
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Zhang, Y., Xu, J., Ruan, Y. C., Yu, M. K., O'Laughlin, M., Wise, H., Chen, D., Tian, L., Shi, D., Wang, J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4162 · Cited by 1,051
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Self-citationOsteoclast differentiation by RANKL and OPG signaling pathways
Udagawa, N., Koide, M., Nakamura, M., Nakamichi, Y., Yamashita, T., Uehara, S., Kobayashi, Y., Furuya, Y., Yasuda, H., Fukuda, C., et al. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01162-6 · Cited by 708
Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms
Booth, F. W., Roberts, C. K., Thyfault, J. P., Ruegsegger, G. N., & Toedebusch, R. G. (2017) · Physiological Reviews · doi:10.1152/physrev.00019.2016 · Cited by 696
Bone morphogenetic proteins: a critical review
Bragdon, B., Moseychuk, O., Saldanha, S., King, D., Julian, J., & Nohe, A. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.003 · Cited by 691
Secreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 628
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
Kramer, I., Halleux, C., Keller, H., Pegurri, M., Gooi, J. H., Weber, P. B., Feng, J. Q., Bonewald, L. F., & Kneissel, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01428-09 · Cited by 567
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
The myokine irisin increases cortical bone mass
Colaianni, G., Cuscito, C., Mongelli, T., Pignataro, P., Buccoliero, C., Liu, P., Lu, P., Sartini, L., Di Comite, M., Mori, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516622112 · Cited by 515
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Tu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
Self-citationLrp5 functions in bone to regulate bone mass
Cui, Y., Niziolek, P. J., MacDonald, B. T., Zylstra, C. R., Alenina, N., Robinson, D. R., Zhong, Z., Matthes, S., Jacobsen, C. M., Conlon, R. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2388 · Cited by 453
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
WNT–β-catenin signalling — a versatile player in kidney injury and repair
Schunk, S. J., Floege, J., Fliser, D., & Speer, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00343-w · Cited by 427
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Self-citationSclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Self-citationRelation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 397
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 390
Osteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
“Mice with targeted deletion of the Sost gene display progressive high bone mass and increased bone strength [18, 19], whereas transgenic mice overexpressing human SOST exhibit low bone mass [15, 20, 21].”
Esen, E., Chen, J., Karner, C. M., Okunade, A. L., Patterson, B. W., & Long, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.017 · Cited by 367
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Wnt signaling in bone formation and its therapeutic potential for bone diseases
Kim, J. H., Liu, X., Wang, J., Chen, X., Zhang, H., Kim, S. H., Cui, J., Li, R., Zhang, W., Kong, Y., et al. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12466608 · Cited by 356
Stimulation of Piezo1 by mechanical signals promotes bone anabolism
Li, X., Han, L., Nookaew, I., Mannen, E., Silva, M. J., Almeida, M., & Xiong, J. (2019) · eLife · doi:10.7554/elife.49631 · Cited by 353
Self-citationThe Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Baron, R., & Hesse, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2332 · Cited by 320
Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2186 · Cited by 311
Mirza, F. S., Padhi, I. D., Raisz, L. G., & Lorenzo, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 311
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice
Colaianni, G., Mongelli, T., Cuscito, C., Pignataro, P., Lippo, L., Spiro, G., Notarnicola, A., Severi, I., Passeri, G., Mori, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02557-8 · Cited by 303
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Ramos Fuentes, F. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 301
Hassan, M. Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J. A. R., Li, Z., Croce, C. M., van Wijnen, A. J., Stein, J. L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377515 · Cited by 297
Wnt signaling and cellular metabolism in osteoblasts
Karner, C. M., & Long, F. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2425-5 · Cited by 295
Recker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A., Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2351 · Cited by 293
The role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
Basis of bone metabolism around dental implants during osseointegration and peri‐implant bone loss
Insua, A., Monje, A., Wang, H., & Miron, R. J. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36060 · Cited by 277
Zhu, D., Mackenzie, N. C. W., Millán, J. L., Farquharson, C., & MacRae, V. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019595 · Cited by 276
Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. (2008) · Development · doi:10.1242/dev.025825 · Cited by 275
Osteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
Ominsky, M. S., Li, C., Li, X., Tan, H. L., Lee, E., Barrero, M., Asuncion, F. J., Dwyer, D., Han, C.-Y., Vlasseros, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
Self-citationThe osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Self-citationWoo, S. M., Rosser, J., Dusevich, V., Kalajzic, I., & Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.465 · Cited by 243
Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets
Marie, P. J., & Kassem, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0132 · Cited by 234
The WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
‘Adipaging’: ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue
Pérez, L. M., Pareja‐Galeano, H., Sanchis‐Gomar, F., Emanuele, E., Lucia, A., & Gálvez, B. G. (2016) · The Journal of Physiology · doi:10.1113/jp271691 · Cited by 215
Osteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Suppression of Autophagy in Osteocytes Mimics Skeletal Aging
Onal, M., Piemontese, M., Xiong, J., Wang, Y., Han, L., Ye, S., Komatsu, M., Selig, M., Weinstein, R. S., Zhao, H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444190 · Cited by 206
Kamiya, N., Kobayashi, T., Mochida, Y., Yu, P. B., Yamauchi, M., Kronenberg, H. M., & Mishina, Y. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090806 · Cited by 198
Effects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes
Wein, M. N., Spatz, J., Nishimori, S., Doench, J., Root, D., Babij, P., Nagano, K., Baron, R., Brooks, D., Bouxsein, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2381 · Cited by 158
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Stegen, S., Stockmans, I., Moermans, K., Thienpont, B., Maxwell, P. H., Carmeliet, P., & Carmeliet, G. (2018) · Nature Communications · doi:10.1038/s41467-018-04679-7 · Cited by 126
Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114
Lyons, J. S., Joca, H. C., Law, R. A., Williams, K. M., Kerr, J. P., Shi, G., Khairallah, R. J., Martin, S. S., Konstantopoulos, K., Ward, C. W., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan5748 · Cited by 106
Moriishi, T., Fukuyama, R., Ito, M., Miyazaki, T., Maeno, T., Kawai, Y., Komori, H., & Komori, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040143 · Cited by 105
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Ominsky, M. S., Brown, D. L., Van, G., Cordover, D., Pacheco, E., Frazier, E., Cherepow, L., Higgins-Garn, M., Aguirre, J. I., Wronski, T. J., et al. (2015) · Bone · doi:10.1016/j.bone.2015.08.007 · Cited by 93
Self-citationTransferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling
Rauner, M., Baschant, U., Roetto, A., Pellegrino, R. M., Rother, S., Salbach-Hirsch, J., Weidner, H., Hintze, V., Campbell, G., Petzold, A., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0005-8 · Cited by 87
Update in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Bassett, J. H. D., Gogakos, A., White, J. K., Evans, H., Jacques, R. M., van der Spek, A. H., Sanger Mouse Genetics Project, Ramirez-Solis, R., Ryder, E., Sunter, D., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002858 · Cited by 82
Farr, J. N., Charkoudian, N., Barnes, J. N., Monroe, D. G., McCready, L. K., Atkinson, E. J., Amin, S., Melton, L. J., Joyner, M. J., & Khosla, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2381 · Cited by 79
Romosozumab for the treatment of osteoporosis
McClung, M. R. (2018) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2018.03.002 · Cited by 78
SOST/Sclerostin improves posttraumatic osteoarthritis and inhibits MMP2/3 expression after injury
Chang, J. C., Christiansen, B. A., Murugesh, D. K., Sebastian, A., Hum, N. R., Collette, N. M., Hatsell, S., Economides, A. N., Blanchette, C. D., & Loots, G. G. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3397 · Cited by 58
IGFBP-4 regulates adult skeletal growth in a sex-specific manner
Maridas, D. E., DeMambro, V. E., Le, P. T., Nagano, K., Baron, R., Mohan, S., & Rosen, C. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0673 · Cited by 47
Serum sclerostin in alcoholics: a pilot study
González-Reimers, E., Martín-González, C., de la Vega-Prieto, M. J., Pelazas-González, R., Fernández-Rodríguez, C., López-Prieto, J., Alvisa-Negrín, J., & Santolaria-Fernández, F. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/ags136 · Cited by 41
Stein, M., Elefteriou, F., Busse, B., Fiedler, I. A., Kwon, R. Y., Farrell, E., Ahmad, M., Ignatius, A., Grover, L., Geris, L., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4868 · Cited by 42
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Silverman, S. L. (2010) · Journal of Osteoporosis · doi:10.4061/2010/941419 · Cited by 30
Bone marrow adipoq+ cell population controls bone mass via sclerostin in mice
Gao, H., Zhong, Y., Lin, S., Yan, Q., Zou, X., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01461-0 · Cited by 19
Imamura, K., Maeda, S., Kawamura, I., Matsuyama, K., Shinohara, N., Yahiro, Y., Nagano, S., Setoguchi, T., Yokouchi, M., Ishidou, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520585 · Cited by 19
Jörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
Osteocyte Wnt/β-catenin pathway activation upon mechanical loading is altered in ovariectomized mice
Jackson, E., Lara-Castillo, N., Akhter, M. P., Dallas, M., Scott, J. M., Ganesh, T., & Johnson, M. L. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101129 · Cited by 13
Metadata
- Authors
- Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., Asuncion, F., Barrero, M., Warmington, K., Dwyer, D., Stolina, M., Morony, S., Sarosi, I., Kostenuik, P. J., Lacey, D. L., Simonet, W. S., Ke, H. Z., & Paszty, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-01
- Volume
- 23
- Issue
- 6
- Pages
- 860-869
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2068916684
- Cited by
- 936
- References
- 28
- FWCI
- 52.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.